This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Harnek J, James S, Lagerqvist B. Coronary Artery Perforation and Tamponade ― Incidence, Risk Factors, Predictors and Outcomes From 12 Years’ Data of the SCAAR Registry ―. Circulation Journal. 2020;84(1):43–53.HarnekJJamesSLagerqvistBCoronary Artery Perforation and Tamponade ― Incidence, Risk Factors, Predictors and Outcomes From 12 Years’ Data of the SCAAR Registry ―Circulation Journal20208414353Search in Google Scholar
Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med. 2015;8:43–61.BeitelsheesALVooraDLewisJPPersonalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsPharmgenomics Pers Med201584361Search in Google Scholar
Siasos G, Oikonomou E, Zaromitidou M, Kioufis S, Kokkou E, Mourouzis K, et al. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. Atherosclerosis. 2015;242(1):102–8.SiasosGOikonomouEZaromitidouMKioufisSKokkouEMourouzisKClopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapyAtherosclerosis201524211028Search in Google Scholar
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. New England Journal of Medicine. 2018;379(3):215–25.JohnstonSCEastonJDFarrantMBarsanWConwitRAElmJJClopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIANew England Journal of Medicine2018379321525Search in Google Scholar
Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics. 2020;21(12):889–97.EllithiMBayeJWilkeRACYP2C19 genotype-guided antiplatelet therapy: promises and pitfallsPharmacogenomics2020211288997Search in Google Scholar
Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98(2):100–8.ZabalzaMSubiranaISalaJLluis-GanellaCLucasGTomásMMeta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrelHeart20129821008Search in Google Scholar
Zhu WY, Zhao T, Xiong XY, Li J, Wang L, Zhou Y, et al. Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia. Sci Rep. 2016;6(25478).ZhuWYZhaoTXiongXYLiJWangLZhouYAssociation of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in AsiaSci Rep2016625478Search in Google Scholar
Amin AM, Sheau Chin L, Azri Mohamed Noor D, Sk Abdul Kader MA, Kah Hay Y, Ibrahim B. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiology Research and Practice. 2017;2017:8062796.AminAMSheau ChinLAzri Mohamed NoorDSk Abdul KaderMAKah HayYIbrahimBThe Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and PharmacometabolomicsCardiology Research and Practice201720178062796Search in Google Scholar
Qian W, Chen L, Zhang L, Gao M, Wang C, Qian X, et al. Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele. J Thorac Dis. 2022;14(7):2591–601.QianWChenLZhangLGaoMWangCQianXComparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function alleleJ Thorac Dis20221472591601Search in Google Scholar
Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959–67.LeeCRLuzumJASangkuhlKGammalRSSabatineMSSteinCMClinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 UpdateClin Pharmacol Ther2022112595967Search in Google Scholar
Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, et al. Very important pharmacogene summary. Pharmacogenetics and Genomics. 2011;21(3):152–61.HodgesLMMarkovaSMChinnLWGowJMKroetzDLKleinTEVery important pharmacogene summaryPharmacogenetics and Genomics201121315261Search in Google Scholar
Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012;7(10):9.SuJXuJLiXZhangHHuJFangRABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysisPLoS One20127109Search in Google Scholar
Stokanovic D, Nikolic VN, Konstantinovic SS, Zvezdanovic JB, Lilic J, Apostolovic SR, et al. P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. Pharmacology. 2015;97(3–4):101–6.StokanovicDNikolicVNKonstantinovicSSZvezdanovicJBLilicJApostolovicSRP-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel ConcentrationPharmacology2015973–41016Search in Google Scholar
Wang X-q, Shen C-l, Wang B-n, Huang X-h, Hu Z-l, Li J. Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2015;558(2):200–7.WangX-qShenC-lWangB-nHuangX-hHuZ-lLiJGenetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndromeGene201555822007Search in Google Scholar
Hidayat R, Rasyid A, Harris S, Harahap A, Herqutanto, Louisa M, et al. Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients. Vasc Health Risk Manag. 2023;19:53–61.HidayatRRasyidAHarrisSHarahapAHerqutantoLouisaMCorrelation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke PatientsVasc Health Risk Manag2023195361Search in Google Scholar
Su J, Yu Q, Zhu H, Li X, Cui H, Du W, et al. The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS One. 2017;12(3).SuJYuQZhuHLiXCuiHDuWThe risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han populationPLoS One2017123Search in Google Scholar
Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon T, et al. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2019;76(5):552–60.PanYChenWWangYLiHJohnstonSCSimonTAssociation Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical TrialJAMA Neurol201976555260Search in Google Scholar
Adamiak-Giera U, Czerkawska A, Olędzki S, Kurzawski M, Safranow K, Jastrzębska M, et al. Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention. Pharmacological Reports. 2021;73(2):583–93.Adamiak-GieraUCzerkawskaAOlędzkiSKurzawskiMSafranowKJastrzębskaMImpact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary interventionPharmacological Reports202173258393Search in Google Scholar
Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. Jama. 2011;306(20):2221–8.MegaJLHochholzerWFrelingerALKlukMJAngiolilloDJKereiakesDJDosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular DiseaseJama20113062022218Search in Google Scholar
Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75.SimonTVerstuyftCMary-KrauseMQuteinehLDrouetEMéneveauNGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med2009360436375Search in Google Scholar
Rossini R, Capodanno D, Musumeci G, Lettieri C, Lortkipanidze N, Romano M, et al. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis. 2011;22(3):199–205.RossiniRCapodannoDMusumeciGLettieriCLortkipanidzeNRomanoMSafety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantationCoron Artery Dis2011223199205Search in Google Scholar